192 related articles for article (PubMed ID: 21989182)
1. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
Gormley JA; Hegarty SM; O'Grady A; Stevenson MR; Burden RE; Barrett HL; Scott CJ; Johnston JA; Wilson RH; Kay EW; Johnston PG; Olwill SA
Br J Cancer; 2011 Nov; 105(10):1487-94. PubMed ID: 21989182
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
[TBL] [Abstract][Full Text] [Related]
4. MiR-320e is a novel prognostic biomarker in colorectal cancer.
Perez-Carbonell L; Sinicrope FA; Alberts SR; Oberg AL; Balaguer F; Castells A; Boland CR; Goel A
Br J Cancer; 2015 Jun; 113(1):83-90. PubMed ID: 26035698
[TBL] [Abstract][Full Text] [Related]
5. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
Chau I; Norman AR; Cunningham D; Tait D; Ross PJ; Iveson T; Hill M; Hickish T; Lofts F; Jodrell D; Webb A; Oates JR
Ann Oncol; 2005 Apr; 16(4):549-57. PubMed ID: 15695501
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.
Myklebust MP; Li Z; Tran TH; Rui H; Knudsen ES; Elsaleh H; Fluge Ø; Vonen B; Myrvold HE; Leh S; Tveit KM; Pestell RG; Dahl O
Br J Cancer; 2012 Nov; 107(10):1684-91. PubMed ID: 23099809
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Cascinu S; Georgoulias V; Kerr D; Maughan T; Labianca R; Ychou M
Ann Oncol; 2003; 14 Suppl 2():ii25-9. PubMed ID: 12810454
[TBL] [Abstract][Full Text] [Related]
12. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
19. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
Deng Y; Wang L; Tan S; Kim GP; Dou R; Chen D; Cai Y; Fu X; Wang L; Zhu J; Wang J
Mol Oncol; 2015 Aug; 9(7):1341-7. PubMed ID: 25864038
[TBL] [Abstract][Full Text] [Related]
20. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
Eur J Cancer; 2014 Nov; 50(17):2966-74. PubMed ID: 25266443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
